Nektar Therapeutics (NASDAQ:NKTR) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 ...
eLife13h
Expression of a single inhibitory member of the Ly49 receptor family is sufficient to license NK cells for effector functions
A novel mouse model offers definitive evidence that a single inhibitory receptor family governs the critical natural killer cell functions of licensing and missing-self.